



October 17, 2024

Dear Valued Baxter Customer,

We are writing to provide you with information intended to assist you in making important decisions involving the treatment of your patients.

Due to higher-than normal demand, Baxter is implementing a protective allocation on certain products in our Pharmacy portfolio. Please see the list of products affected in the appendix.

We will be implementing a 125% allocation based on historical ordering made between April 2024 - September 2024. Any quantity ordered that exceeds your allocation will be automatically canceled.

Baxter is making every effort to supply clinicians with products as quickly as possible.

We are committed to transparently and proactively communicating any changes in supply to you. In the meantime, to ensure you have the information you need readily available, please visit the [Supply Resources](https://ushospitalproducts.baxter.com/baxter-supply-resources) page on our website and download our Supply Availability Report to access the latest information on product supply.

(<https://ushospitalproducts.baxter.com/baxter-supply-resources>)

Please contact Baxter's Medical Information if you have clinical questions regarding the Pharmacy Portfolio, at 1-800-422-2751. For any additional questions about your order, please contact your Baxter Sales Representative or Baxter's Center for Service at 1-888-229-0001.

Again, we appreciate your patience and support as we work through these difficult times together.

Sincerely,

A handwritten signature in black ink that reads "Joanne Manidis". The signature is written in a cursive, flowing style.

Joanne Manidis
GM, Pharmaceuticals – North America

APPENDIX:

Product Description	Total Strength / Total Volume	Product Code	National Drug Code	P/F	Allocation
CARDENE I.V. (nicardipine hydrochloride) in 0.86% Sodium Chloride	20 mg/200 mL	2G3443	43066-009-10	10	125%
CARDENE I.V. (nicardipine hydrochloride) in 0.83% Sodium Chloride	40 mg/200 mL	2G3444	43066-016-10	10	125%
CARDENE I.V. (nicardipine hydrochloride) in 0.86% Sodium Chloride NOVAPLUS	20 mg/200 mL	2G3445	43066-021-10	10	125%
CARDENE I.V. (nicardipine hydrochloride) in 0.83% Sodium Chloride NOVAPLUS	40 mg/200 mL	2G3446	43066-024-10	10	125%
NEXTERONE (amiodarone HCl) Premixed Injection	150 mg/100 mL	2G3451	43066-150-10	12	125%
	360 mg/200 mL	2G3450	43066-360-20	10	125%
Norepinephrine Bitartrate in 5% Dextrose Injection	4 mg/250 mL	EZPE7748	0338-0112-20	20	125%
	8 mg/250 mL	EZPE7788	0338-0108-20	20	125%
Cefazolin Injection, USP	1 g/50 mL	2G3503	0338-3503-41	24	125%
	2 g/100 mL	2G3508	0338-3508-41	12	125%
Cefepime Injection	1 g/50 mL	2G3578	0338-1301-41	24	125%
	2 g/100 mL	2G3579	0338-1301-48	12	125%
Ceftriaxone Injection, USP (in 5% Dextrose)	1 g/50 mL	2G3504	0338-5002-41	24	125%
	2 g/50 mL	2G3505	0338-5003-41	24	125%
Daptomycin in 0.9% Sodium Chloride Injection	350 mg/50 mL	2G3593	0338-0712-24	24	125%
	500 mg/50 mL	2G3594	0338-0714-24	24	125%
	700 mg/100 mL	2G3595	0338-0716-12	12	125%
	1,000 mg/100 mL	2G3596	0338-0718-12	12	125%
Nafcillin Injection, USP	2 g/100 mL	2G3556	0338-1019-48	12	125%
Oxacillin Injection, USP	2 g/50 mL	2G3539	0338-1015-41	24	125%
Penicillin G Potassium Injection, USP	2,000,000 units/50 mL	2G3543	0338-1023-41	24	125%
	3,000,000 units/50 mL	2G3544	0338-1025-41	24	125%
Vancomycin Injection, USP (in 5% Dextrose)	500 mg/100 mL	2G3551	0338-3551-48	12	125%
	750 mg/150 mL	2G3580	0338-3580-48	6	125%
	1 g/200 mL	2G3552	0338-3552-48	6	125%
	1.25 g/250 mL	2G3557	0338-0122-04	4	125%
	1.5 g/300 mL	2G3558	0338-0124-04	4	125%
Vancomycin Injection, USP (in 0.9% Sodium Chloride)	500 mg/100 mL	2G3590	0338-3581-01	12	125%
	750 mg/150 mL	2G3591	0338-3582-01	6	125%
	1 g/200 mL	2G3592	0338-3583-01	6	125%
ZOSYN (piperacillin and tazobactam) Injection	2.25 g/50 mL	2G3582	0338-9632-24	24	125%
	3.375 g/50 mL	2G3583	0338-9636-24	24	125%
	4.5 g/100 mL	2G3584	0338-9638-12	12	125%